R&D Investments, Pending Approvals, Acquisitions - Research Report on Optimer, Zogenix, Cubist, Merck and Questcor

Mon Mar 4, 2013 8:01am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130304:nPn3045835


NEW YORK,  March 4, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Optimer
Pharmaceuticals, Inc. (NASDAQ: OPTR), Zogenix, Inc. (NASDAQ: ZGNX), Cubist
Pharmaceuticals Inc (NASDAQ: CBST), Merck & Co., Inc. (NYSE: MRK) and Questcor
Pharmaceuticals, Inc. (NYSE: QCOR). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Optimer Pharmaceuticals, Inc. Research Report

Optimer shares rallied 13 percent following news that one of its "strategic
alternatives to maximize shareholder value" was to consider a possible sale. The
company's CEO  Pedro Lichtinger  will also resign and will be replaced on an
interim basis by former Pfizer Inc. CEO  Henry A. McKinnell Jr.  According to 
Brian Skorney, an analyst for Robert W. Baird & Co., the company may be a target
for Pfizer or Johnson & Johnson. Furthermore, data compiled by Bloomberg states
that the company's revenue is projected to more than double to  $310 million  by
the end of 2017 from 2011. Fourth quarter earnings were  2 cents  per share
against an estimate of a  55 cent  loss. With a change in leadership and a
possible sale, many analysts and investors are optimistic about Optimer's
future. The company's full report will The Full Research Report on Optimer
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/757e_OPTR]

--

Zogenix, Inc. Research Report

Zogenix announced that the FDA has delayed approval for its Zohydro drug, a
long-acting version of the painkiller hydrocone. The FDA did not comment the
cause of the delay but stated that it would most likely be brief and may last
only for several weeks. Many remain optimistic that the FDA will approve the
drug, including Wells Fargo analyst  Michael Tong. He comments, "We continue to
believe the odds for eventual approval are high. We speculate FDA is dealing
with issues of access and potential misuse." If approved, the drug will be the
first pure hydrocone medication in  the United States, showing the potential of
this drug to generate returns for the company. The Full Research Report on
Zogenix, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/d33e_ZGNX]

--

Cubist Pharmaceuticals Inc Research Report

Cubist announced that it has entered into an option agreement with Adynxx in
which Cubist will have exclusive right to acquire Adynxx following the data
readout of Adynxx's Phase II trial for AYX1. Cubist is impressed with the Phase
I results and believes that the drug may be a new therapy for post-surgical and
chronic pain. Cubist will pay Adynxx to secure exclusive rights to acquire the
company with cash on hand, and additional payments will be made to Adynxx
shareholders if Cubist chooses to exercise its right to acquire Adynxx.  This is
one of Cubist's strategic efforts to strengthen its pipeline. The Full Research
Report on Cubist Pharmaceuticals Inc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/0f29_CBST]

--

Merck & Co., Inc. Research Report

To strengthen its pipeline, Merck has entered into a biosimilars development
project and commercialization agreement with Samsung Bioepis Co., Ltd.
Biosimilars, or generic biologics, are drugs with active substances made from
living organisms. With their combined resources, the two companies aim to
promote public access to biosimilars. Furthermore, Merck presented new data
regarding its allergic rhinitis treatment. Developing its pipeline allows the
company to assure long-term growth and continue returning healthy dividends to
investors. Its most recent dividend was announced at  43 cents  per share,
payable  April 5, 2013. The Full Research Report on Merck & Co., Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/d004_MRK]

--

Questcor Pharmaceuticals, Inc. Research Report

Questcor Pharmaceuticals reported earnings that beat estimates, with adjusted
earnings per share of  $1.09, up 132 percent from the same quarter a year ago.
The company's Acthar drug was the main driver for growth. Acthar sales were up
94 percent compared to 2011. In the coming year, Questcor intends to continue
investing in R&D programs and increase manufacturing capabilities. The company
is presently working on approximately 35 research projects, including some Phase
4 projects. Lastly, the company has been repurchasing shares in order to provide
higher returns to investors. The Full Research Report on Questcor
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investors-alliance.com/r/full_research_report/21da_QCOR]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email:  press@Investors-Alliance.com

Main: +1-480-745-7826

SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.